Cantitate/Preț
Produs

Amiloid Cardiomyopathies: Clinical, Diagnostic and Therapeutic Aspects, An Issue of Heart Failure Clinics: The Clinics: Internal Medicine, cartea 20-3

Editat de Giuseppe Limongelli, Michele Emdin, Marco Merlo, Emanuele Monda
en Limba Engleză Hardback – 12 iun 2024
In this issue of Heart Failure Clinics, guest editors Drs. Giuseppe Limongelli, Michele Emdin, Marco Merlo, and Claudio Rapezzi bring their considerable expertise to the topic of Amyloid Cardiomyopathies: Clinical, Diagnostic and Therapeutic Aspects. Top experts in the field discuss the role of clinical use of biomarkers in cardiac amyloidosis; cardiac magnetic resonance in the management of cardiac amyloidosis; bone scintigraphy: strength points and pitfalls in the diagnosis of ATTR-cardiac amyloidosis; PET and cardiac amyloidosis; endomyocardial biopsy in the diagnosis of cardiac amyloidosis; and much more.
Citește tot Restrânge

Din seria The Clinics: Internal Medicine

Preț: 51809 lei

Preț vechi: 54536 lei
-5% Nou

Puncte Express: 777

Preț estimativ în valută:
9915 10299$ 8236£

Carte disponibilă

Livrare economică 11-25 ianuarie 25
Livrare express 28 decembrie 24 - 03 ianuarie 25 pentru 3268 lei

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780443121432
ISBN-10: 0443121435
Pagini: 240
Dimensiuni: 178 x 254 x 11 mm
Greutate: 0.42 kg
Editura: Elsevier
Seria The Clinics: Internal Medicine


Cuprins

Amyloidosis and Amyloidogenesis: One Name, Many Diseases
Pathophysiology of Cardiac Amyloidosis
The Role of Echocardiography for the Clinical Diagnosis, Risk Stratification, and Management of Cardiac Amyloidosis
Clinical Use of Biomarkers in Cardiac Amyloidosis
Cardiovascular Magnetic Resonance in the Management of Cardiac Amyloidosis: Current and Future Clinical Applications
The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis
Genotype-Phenotype Correlations in ATTR Amyloidosis: A Clinical Update
Standard Therapy in Cardiac Amyloidosis: What is Known, What is “Gray”
Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones
Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis